ReviewFrontiers in immunology2022
CD47 as a promising therapeutic target in oncology.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 48 citations in OpenAlex.
- Recent advances in the regulation of CD47 by non-coding RNAs and its therapeutic potential in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- The neuroimmune network in Alzheimer's and Parkinson's diseases: from mechanistic insights to biomarker-guided immunotherapies and clinical translation.Inflammopharmacology · 2026Review
- Erythrocyte-inspired biomaterials for cancer immunotherapy: Integration within the cancer-immunity cycle.Materials today. Bio · 2026Review
- Targeting the CD47-SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next-generation therapeutic strategies.Smart molecules : open access · 2026Review
- Rewiring tumor metabolism: heterogeneity, oncometabolites, and adaptive plasticity.Experimental hematology & oncology · 2026Review
- Podophyllotoxin sensitizes triple-negative breast cancer cells to CD47-targeted immunotherapy.Cell insight · 2026Article
- Biomimetic cancer cell membrane-coated liposomal nanocarriers loaded with silibinin suppress gastric cancer progression via SNHG1/miR-383-5p/HSP90AA1 axis-mediated PI3K/AKT pathway inhibition.Materials today. Bio · 2026Article
- Nanotechnology for atherosclerotic plaque stabilisation: bridging innovation and clinical practice.EBioMedicine · 2026Review
- CD47 blockade (ALX301) enhances immunoradiotherapy response in HPV negative head and neck squamous cell carcinoma.PloS one · 2026Article
- Current Status and Future Prospects of Immune Checkpoint Inhibitors Research in the Treatment of Multiple Myeloma.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Review
- Targeted biomimetic fusogenic liposome enhances tumor accumulation, penetration, and therapeutic efficacy of siRNA therapeutics.Materials today. Bio · 2025Article
- Targeting the CD47-TSP1 Axis in Abdominal Aortic Aneurysm: A Novel Immunotherapeutic Approach.International journal of molecular sciences · 2025Review
- Advances in constructing biocompatible nanocarriers.Drug delivery and translational research · 2025Review
- Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile.Molecular cancer therapeutics · 2025Article
- Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia.Annals of hematology · 2025Article
- A CD47 antibody with minimized erythrocyte and thrombocyte toxicities.Frontiers in oncology · 2025Article
- CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge.Oncology research · 2025Review
- CD47: an immunoregulatory nexus in liver and gastrointestinal disorders.eGastroenterology · 2025Review
- Role ofJournal for immunotherapy of cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipulates synaptic pruning during neuronal development. As such, CD47 has recently be regarded as one of novel innate checkpoint receptor targets for cancer immunotherapy. In this review, we will discuss increasing awareness about the diverse functions of CD47 and its role in immune system homeostasis. Then, we will discuss its potential therapeutic roles against cancer and outlines, the possible future research directions of CD47- based therapeutics against cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.